

**Access to Healthcare**

1. [Indian healthcare industry's demand for workforce to double to 7.4 million in 2022](#) – The Times of India
2. [West Bengal to distribute free cancer drugs to poor](#) – Business Standard

**Medical & Regulatory**

1. [Govt to curb prescription and sale of antibiotics to combat drug resistance](#) – The Times of India
2. [CDSCO sub-committee for online pharmacy to meet on September 7, slated to deliberate on dedicated norms](#) – Pharmabiz.com
3. [Companies recall 'Made in India' drugs for subpotency, impurities and more](#) - DNA

**Others**

1. [Cipla: the American dream](#) – Mint
- 

**Access to Healthcare**

1. [Indian healthcare industry's demand for workforce to double to 7.4 million in 2022](#) – The Times of India  
The Indian healthcare industry is seeing a robust growth trajectory and is expected to grow vigorously at a CAGR of 16 per cent from \$73.92 billion in 2011 to \$280 billion in 2020, said FICCI-KPMG report 'Healthcare: The neglected GDP driver.' The report was recently released by the minister of state for development of northeast region and minister of state for prime minister office, Jitendra Singh, at the two-day FICCI Annual flagship Healthcare Conference - FICCI HEAL 2015.

2. [West Bengal to distribute free cancer drugs to poor](#) – Business Standard  
Expensive [cancer](#) drugs will be distributed to poor patients free-of-cost by the state government from next month, [West Bengal](#) Health Minister [Chandrima Bhattacharya](#) said on Saturday.

"The decision would be implemented from October 2," Bhattacharya said, adding that the drugs would be available in state-run hospitals

**Medical & Regulatory**

1. [Govt to curb prescription and sale of antibiotics to combat drug resistance](#) - The Times of India  
The government may soon issue restrictions on prescription and sale of commonly used antibiotics in an attempt to avoid development of drug resistance to infectious diseases like tuberculosis, malaria, urinary tract infection and even HIV. This means [doctors and chemists will have to follow certain mandatory protocols and guidelines while prescribing antibiotics](#). For instance, chemists will have to maintain records of all kinds of antibiotics that they procure and sell along with the doctor's prescription. The move is part of the new global strategy, adopted by all member countries of the World Health Organization, to fight drug-resistant diseases.

2. [CDSCO sub-committee for online pharmacy to meet on September 7, slated to deliberate on dedicated norms](#) – Pharmabiz.com

CDSCO which has constituted the sub-committee to scrutinise the concerns of permitting the online pharmacy business model under the purview of the Drugs and Cosmetic Rules 1945 will now meet on September 7, 2015 at Mumbai. Following the 48th meeting of the Drugs Consultative Committee held on July 24, 2015, the formation of a dedicated sub-committee came into being. The sub-committee has been intimated by the CDSCO that within the next three months, it will need to furnish its report about the importance of online pharmacy in the current context of advancements in information technology and the internet along with a set of norms that would enable the players in the space to stay compliant.

3. [Companies recall 'Made in India' drugs for subpotency, impurities and more](#) – DNA

As per the recent notifications by the US Food and Drug Administration (FDA), Indian pharma companies and multinationals manufacturing at India plants have initiated voluntary drug recalls for a number of drugs in the US market. Hyderabad-based Dr Reddy's Laboratories has initiated voluntary recall of a total of 55,344 bottles of high blood pressure drug amlodipine besylate and atorvastatin calcium tablets in various dosages manufactured in its facility at Bachupally. The reason of the ongoing Class III recall, which was initiated on August 13, 2015, was given as subpotent drug of atorvastatin. In a Class III recall, use of or exposure to a violative product is not likely to cause adverse health consequences.

## Others

1. [Cipla: the American dream](#) – Mint

With the acquisition, Cipla gets a ready base to launch, promote and distribute products to the government and institutions in the US, while adding \$225 million in sales to own revenue, giving it more scale and reach. Some of India's bigger generic drug makers are experiencing mid-life jitters in the US market as sales growth slows down due to a variety of reasons. Yet, this is the time when Cipla Ltd is aiming to make it big in this still-lucrative pharmaceutical market. It is paying \$550 million, or Rs.3,650 crore, to buy two US-based generic companies owned by the promoters of Hetero Drugs Ltd.